Article Text

Download PDFPDF

294 Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19
  1. M Smith1,
  2. O Lara1,
  3. R O’Cearbhaill2,
  4. M Sutter3,
  5. A Knisely4,
  6. J McEachron5,
  7. L Gabor6,
  8. C Carr7,
  9. S Blank7,
  10. M Prasad-Hayes7,
  11. M Frey8,
  12. J Jee2,
  13. J Fehniger1,
  14. YC Lee5,
  15. S Isani4,
  16. J Wright4 and
  17. B Pothuri1
  1. 1Department of Obstetrics and Gynecology, NYU Langone Health, USA
  2. 2Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, USA
  3. 3Department of Population Health, NYU Langone Health, USA
  4. 4Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, USA
  5. 5Department of Obstetrics and Gynecology, State University of New York Downstate Medical Center, USA
  6. 6Department of Obstetrics and Gynecology and Women’s Health, Montefiore Medical Center and Albert Einstein College of Medicine, USA
  7. 7Department of Obstetrics and Gynecology, Mount Sinai Hospital System, USA
  8. 8Department of Obstetrics and Gynecology, Weill Cornell Medicine, USA


Introduction Elevated inflammatory markers in COVID-19 infection are predictive of disease severity and mortality. It is unclear if these markers are associated with severe disease in patients with cancer due to underlying tumor related inflammation. We sought to further understand the inflammatory response related to COVID-19 in gynecologic cancer patients.

Methods Patients with history of gynecologic cancer hospitalized for COVID-19 infection with available laboratory data were identified. Laboratory values at the time of hospital admission and clinical outcomes were abstracted from electronic medical records. Severe infection was defined as infection requiring ICU admission or resulting in death.

Results 86 patients with gynecologic cancer were hospitalized with COVID-19 infection with median age of 68.5 years (interquartile range (IQR), 59.0 to 74.8 years). Of the 86 patients, 29 (33.7%) patients required ICU admission and 25 (29.1%) patients died of COVID-19 complications. There were 36 (41.9%) patients in remission and 50 (58.1%) had active disease. Patients with severe infection had significantly higher ferritin (median 1163.0, IQR 640.0–1967.0) and C-reactive protein (CRP) (median 142.0, IQR 62.5–217.1) levels than those with non-severe disease (median 624.0, IQR 269.7–954.0, P=0.01; median 62.3, IQR 13.0–159.1, P=0.02 respectively) (table 1). White blood cell count, absolute neutrophil count, and lactate were also associated with severe disease. Procalcitonin and D-Dimer levels were not significantly associated with severe disease (P=0.2; P=0.7 respectively).

Abstract 294 Table 1

Laboratory data at hospital admission in patients with severe vs. non-severe COVID-19 infection

Conclusion/Implications Inflammatory markers (ferritin and CRP) in gynecologic cancer patients are associated with COVID-19 severity and can be used as prognostic markers at the time of admission.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.